| miR-126在急性髓系白血病中的研究进展 |
| |
| 引用本文： | 王玉姣,苏 楠,李 艳,张 蕊.miR-126在急性髓系白血病中的研究进展[J].现代肿瘤医学,2021,0(22):4036-4040. |
| |
| 作者姓名： | 王玉姣 苏 楠 李 艳 张 蕊 |
| |
| 作者单位： | 中国医科大学附属第一医院血液内科，辽宁 沈阳 110001 |
| |
| 基金项目： | National Natural Science Foundation of China(No.81600117）;国家自然科学基金（编号:81600117）；沈阳市中青年科技创新人才支持计划（编号:RC170525） |
| |
| 摘 要： | 急性髓系白血病（acute myeloid leukemia， AML）是血液系统恶性肿瘤中常见的疾病，尽管化学治疗可以清除骨髓中白血病细胞，多数患者的最终结局仍是复发，甚至死亡。miRNAs对急性髓系白血病的诊断、分型及预后往往有指导性意义，其表达水平对化疗敏感性的影响可以提示是否存在化疗耐药。其中，miR-126作为在造血干细胞及内皮细胞均有特异性表达的miRNA，虽然在干细胞中已有详尽的研究，但在AML分化细胞水平尚无完整和确切定论。本文讨论目前miR-126在急性髓系白血病中研究进展及其对干细胞功能的调控。
|
| 关 键 词： | 急性髓系白血病 miR-126 白血病干细胞 表观遗传学调控 |
Research progress of miR-126 in acute myeloid leukemia |
| |
| WANG Yujiao,SU Nan,LI Yan,ZHANG Rui.Research progress of miR-126 in acute myeloid leukemia[J].Journal of Modern Oncology,2021,0(22):4036-4040. |
| |
| Authors: | WANG Yujiao SU Nan LI Yan ZHANG Rui |
| |
| Affiliation: | Department of Hematology，the First Hospital of China Medical University，Liaoning Shenyang 110001,China. |
| |
| Abstract: | Acute myeloid leukemia（AML）is a common hematopoietic malignancy，althouth leukemia cells of bone marrow can be eliminated after chemotherapy treatment，the outcome of patients is relapse or even death in most of the cases.miRNAs have guiding significance in diagnosis，classification and prognosis of AML.The effect of miRNAs expression on chemotherapy sensitivity can indicate whether there is chemotherapy resistance.miR-126，as a specific expression miRNA in both hematopoietic stem cells and endothelial cells,has been well studied in stem cells,but there is no complete and accurate conclusion at differentiated cells in AML.In this review，we will discuss the research progress of miR-126 in AML and its regulation on stem cell function. |
| |
| Keywords: | acute myeloid leukemia miR-126 leukemia stem cells epigenetic regulation |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
